Latest Nanexa News & Updates

See the latest news and media coverage for Nanexa. We track all announcements, press releases, and industry mentions in real time, all in one place.

Nanexa

Developer of long-acting injectable drug delivery systems

Latest news about Nanexa

April 29 Nanexa

Nanexa publishes interim report for January-March 2026

Reports strong preclinical results for semaglutide formulations, financials show turnover TSEK 1,632 and cash TSEK 73,022. All warrants exercised, yielding SEK 55.7 million.
April 28 Nanexa

Nanexa resolves on set-off of SEK 20 million loan

The Board issues shares and warrants to lenders, converting debt to equity, strengthening the balance sheet and preserving liquidity. Dilution is approximately 3.27% from shares and up to 6.34% total.
April 8 Nanexa

Nanexa issues notice of annual general meeting

The meeting occurs on 12 May 2026 at 3:00 pm in Uppsala, Sweden. Shareholders must register by 7 May 2026. Agenda includes financial statements, board elections, and share issue authorizations.
April 2 Nanexa

Nanexa announces exercise of warrants

All 27,878,788 warrants exercised for 27,878,788 new shares at SEK 2 each, raising SEK 55.7 million before costs. Shares increase to 184,786,535.

April 29 FinanzNachrichten

Nanexa AB: Nanexa publishes interim report for January-March 2026

Opened the year with strong preclinical results for once-monthly and quarterly dosing of semaglutide Significant events during the first quarter of 2026In January, Nanexa announced...
March 26 London Stock Exchange

Nanexa publishes annual report for 2025

Nanexa AB (publ) today announces that the Annual Report for 2025 has been published and is available on the company's website Nanexa AB - Financial...
February 19 Dagens industri

Nanexa turns operating result from minus to plus

Drug-delivery company Nanexa reports an operating result of 16.7 million kronor (minus 12.0) in the fourth quarter of 2025.
January 27 London Stock Exchange

Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation

Nanexa's atomic layer deposition (ALD) platform PharmaShell® demonstrably improves the pharmacokinetic profile of semaglutide injections.Significantly smoother plasma concentration curve could mitigate many common side effects...

Never miss news about Nanexa

Track Nanexa and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Browse news for competitors to Nanexa and other trending companies.